NETRIS Pharma

Strategic area of application
Human Medicine

Application market
Oncology

Activities
Therapeutics, Pharma or Biotech

Technologies
Antibodies - Protein - Peptide

Presentation of company's activity
NETRIS Pharma develops innovative medicine based on the concept of dependence receptors, described by Pr. Patrick Mehlen, leader of the “Apoptose, Cancer and Development” laboratory (Centre Léon Bérard) and co-founder of NETRIS Pharma. NETRIS Pharma has currently one drug candidate in Phase I clinical trial. Drug candidates targeting other dependence receptors are under development. 

Key features of company
- clinical stage biotech - innovative drug candidates for cancer therapy - pioneer for drugs targeting dependence receptors

Recent news
Prix Universal Biotech in 2009

Skills and know-how
Preclinical and clinical development Monoclonal antibodies Oncology Business development

Product pipeline 1

Therapeutic area: Oncology

Phase 1: Ongoing

MA: A

Product pipeline 2

Therapeutic area: Oncology

Preclinical: Ongoing

MA: A

Out-licencing opportunity
NETRIS Pharma has an out-licencing strategy for the innovative drug candidates the company develops. The company is therefore looking for pharmaceutical industries with interest in NETRIS Pharma's programs.